What's the size of the femtech market?

This blog post has been written by the person who has mapped the femtech market in a clean and beautiful presentation

The femtech market represents one of healthcare's fastest-growing sectors, targeting the unique health needs of women through technology-driven solutions.

With market size expanding from $41.07 billion in 2024 to $46.70 billion in 2025, this sector offers substantial opportunities for entrepreneurs and investors. And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What was the total global femtech market size in 2024, and how does it compare to 2025?

The global femtech market reached $41.07 billion in 2024 and is projected to hit $46.70 billion in 2025, representing a robust 13.7% year-over-year growth.

This growth trajectory reflects the increasing digitization of women's healthcare and rising awareness of gender-specific health needs. The market's expansion is particularly driven by North American and European investments in fertility tech, menopause solutions, and AI-powered health tracking applications.

The 2025 figures represent a significant rebound from the funding slowdown experienced in 2021-2023. Multiple research firms confirm this upward trend, with some projecting even higher growth rates due to increased corporate partnerships and healthcare system integrations.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

What are the main segments within femtech, and what were their respective market shares in 2024?

The femtech landscape divides into distinct segments, with reproductive health and pregnancy/nursing care each commanding 37% of the total market in 2024.

If you want updated data about this market, you can download our latest market pitch deck here

Which regions are leading in femtech adoption and spending, and how are those numbers evolving in 2025?

North America dominates femtech spending with 53.64% of global market share in 2024, primarily driven by the United States' advanced digital health infrastructure and high women's health awareness.

The region benefits from established venture capital ecosystems, favorable regulatory frameworks, and strong healthcare reimbursement systems. Major cities like San Francisco, Boston, and New York serve as femtech innovation hubs, hosting companies like Maven Clinic, Elvie, and Natural Cycles' US operations.

Europe represents the second-largest market, with the UK, Germany, and Nordic countries leading adoption. The region's strength lies in comprehensive healthcare systems and progressive policies supporting women's health initiatives. The EU's new digital health certification framework in 2024 has streamlined market entry for femtech solutions.

Asia Pacific emerges as the fastest-growing region in 2025, with India, China, and Southeast Asian countries driving expansion. Rising smartphone penetration, increasing healthcare digitization, and government initiatives supporting women's health contribute to this growth trajectory.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

What is the projected CAGR of the femtech industry from 2025 to 2030 and to 2035?

The femtech industry is projected to grow at a compound annual growth rate of 16.37% from 2025 to 2030, according to Grand View Research, with some sources projecting even higher rates of 17.9% through 2032.

These projections reflect several converging factors: increased healthcare digitization, growing awareness of women's health disparities, and rising investment in AI-driven health solutions. The market's expansion is particularly robust in fertility and menopause tech, where personalized medicine approaches are gaining traction.

Long-term forecasts through 2035 suggest a sustained CAGR of approximately 16%, indicating the market's maturation while maintaining strong growth momentum. This trajectory positions femtech as one of healthcare's most dynamic sectors, outpacing traditional medical device and pharmaceutical growth rates.

The projected growth rates assume continued regulatory support, increased insurance coverage for digital health solutions, and sustained venture capital investment in women's health technologies.

How much venture capital was invested in femtech startups in 2024 and 2025, and what are the trends?

Venture capital investment in femtech reached $2.2 billion in 2024, representing 8.5% of total digital health funding, according to Galen Growth research.

When including broader women's health investments, the total funding reached $10.7 billion in 2024, as reported by SVB. This expanded definition encompasses biopharma companies developing women-specific treatments, medical device manufacturers, and healthcare services targeting female patients.

The investment trend shows a recovery from the 2021-2023 funding slowdown. After peaking in 2020, femtech funding experienced a correction but rebounded strongly in 2024 with increased allocations to precision medicine and biopharma solutions. Series A and B rounds dominated the funding landscape, indicating market maturation beyond early-stage ventures.

Notable 2024 trends include increased corporate venture capital participation, particularly from pharmaceutical companies and healthcare systems. Geographic distribution shows continued US dominance, but European and Asian funds are increasingly active in femtech investments.

What are the revenue forecasts for the top femtech categories over the next 5 and 10 years?

Fertility technology leads revenue projections with the segment expected to grow from $9.12 billion in 2025 to $28.89 billion by 2032, maintaining the 17.9% CAGR observed across the broader market.

Menstrual health technology projects a 14.6% CAGR through 2030, driven by increasing adoption of smart period tracking and menstrual pain management solutions. The segment benefits from growing awareness in emerging markets and product innovation in sustainable menstrual products.

Menopause care represents the fastest-growing category with approximately 16% CAGR projections, reflecting the aging population in developed markets and increasing recognition of menopause as a distinct healthcare need requiring specialized solutions.

Mental health solutions targeting women show strong growth potential, particularly in postpartum depression and anxiety management. Sexual wellness and pelvic health categories, while smaller in absolute terms, demonstrate robust growth rates as social stigma decreases and product innovation accelerates.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

If you want clear information about this market, you can download our latest market pitch deck here

How many new femtech companies were launched in 2024 versus 2025, and in which sub-sectors?

Precise company formation data remains limited due to varying definitions of femtech and private company registration practices, but industry analysis indicates continued startup formation acceleration through mid-2025.

Fertility and menopause subsectors show the highest concentration of new company formation, particularly in Asia Pacific and European markets. AI-driven personalization platforms represent a significant portion of new ventures, reflecting technological advancement and market demand for sophisticated health tracking.

Emerging niches include genomic-based fertility prediction, virtual menopause clinics, and workplace wellness programs targeting female employees. The trend toward B2B solutions is notable, with new companies focusing on employer health plans and healthcare system integrations rather than direct consumer applications.

Geographic distribution shows startup formation shifting beyond traditional Silicon Valley hubs, with significant activity in London, Berlin, Tel Aviv, and Bangalore. This geographic diversification reflects global recognition of femtech market opportunities and varying regulatory environments favoring innovation.

Who are the current top 10 players in the global femtech market, and what were their revenues in 2024?

The femtech market leadership includes both pure-play femtech companies and established healthcare providers expanding into women's health technology solutions.

• Flo Health Inc. - Leading period tracking and fertility app with over 200 million users globally
• Joylux, Inc. - Intimate wellness devices and platforms for women's sexual health
• Natural Cycles USA Corp. - FDA-approved fertility awareness app serving as digital contraception
• Clue by BioWink - Menstrual cycle tracking and reproductive health insights platform
• Ava Science Inc. - Wearable fertility tracking technology and women's health research
• Elvie (Chiaro Technology Ltd.) - Connected devices for pelvic floor health and breastfeeding
• Willow Innovations, Inc. - Wearable breast pumps and nursing technology solutions
• Maven Clinic - Virtual healthcare platform specializing in women's and family health
• TytoCare - AI-powered medical examination devices including women's health applications
• Progyny - Fertility benefits management and treatment services for employers

Individual revenue figures for these companies are not publicly disclosed in aggregate market reports, as many remain privately held or report femtech revenues as part of broader healthcare segments.

What major M&A activity happened in femtech in 2024 and 2025, and how is that impacting market consolidation?

The femtech M&A landscape in 2024-2025 demonstrates increasing consolidation as mature companies acquire specialized capabilities and expand their technology portfolios.

Strategic acquisitions focus on fertility and menopause technology, with healthcare systems and pharmaceutical companies acquiring digital health platforms to enhance patient engagement and clinical outcomes. Notable trends include telehealth platforms acquiring specialized femtech applications and medical device companies integrating software capabilities.

Consolidation patterns show larger femtech companies acquiring smaller competitors to expand geographic reach or add complementary services. For example, period tracking apps are acquiring fertility prediction algorithms, and menopause platforms are integrating mental health support services.

The consolidation trend benefits from increased regulatory clarity and established reimbursement pathways, making femtech companies more attractive acquisition targets for traditional healthcare organizations seeking digital transformation capabilities.

If you want to grasp this market fast, you can download our latest market pitch deck here

What are the key technological innovations driving growth in femtech today, and which are expected to scale by 2026?

Artificial intelligence and machine learning represent the primary technological drivers, enabling personalized fertility prediction, symptom tracking, and treatment recommendations based on individual health data patterns.

Wearable devices and IoT integration are transforming continuous health monitoring, with smart patches for hormone tracking, connected pelvic floor trainers, and advanced fertility monitoring devices providing real-time health insights. These technologies move beyond simple tracking to predictive health management.

Telehealth platforms specifically designed for women's health are scaling rapidly, offering virtual consultations for menopause management, fertility counseling, and mental health support. Integration with electronic health records and clinical decision support systems enhances these platforms' effectiveness.

Digital biomarkers represent an emerging innovation area, using AI-driven analysis of voice patterns, movement data, and physiological signals to identify early indicators of reproductive health issues, cardiovascular risks, and mental health conditions specific to women.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

What regulatory changes occurred in 2024 or are expected in 2025 that could significantly affect the femtech market?

The European Union implemented a comprehensive digital health certification framework in 2024, streamlining approval processes for femtech applications and devices while maintaining rigorous safety and efficacy standards.

The US FDA expanded guidance on software as a medical device specifically for women's health applications, providing clearer pathways for fertility tracking apps, menopause management platforms, and reproductive health monitoring devices to obtain regulatory approval.

Expected 2025 developments include broader reimbursement guidelines for tele-menopause services and fertility support platforms, as insurance providers recognize the cost-effectiveness of preventive digital health interventions. CMS and private insurers are developing coverage criteria for digital therapeutics addressing women's health conditions.

WHO initiatives to standardize HPV vaccination protocols and reproductive health data collection are creating global frameworks that benefit femtech companies operating across multiple markets. These standardization efforts reduce regulatory complexity and enable faster international expansion.

What are the biggest barriers to entry in femtech today, and how might these evolve in the next 5 years?

Clinical evidence requirements represent the most significant barrier, as femtech companies must demonstrate safety and efficacy while managing limited funding for expensive clinical trials.

Data privacy and interoperability challenges create technical barriers, particularly for companies seeking integration with healthcare systems and electronic health records. Compliance with HIPAA, GDPR, and emerging state privacy laws requires substantial legal and technical resources.

Limited reimbursement pathways for digital therapeutics restrict market accessibility, as many innovative femtech solutions lack clear coverage criteria from insurance providers. This financing gap limits customer adoption and company revenue potential.

Regulatory uncertainty in emerging markets and varying international standards create additional complexity for companies seeking global expansion. Different countries maintain distinct approval processes and clinical evidence requirements.

The next five years should bring greater policy clarity, improved public-private partnerships, and expanded insurance coverage, lowering entry barriers and catalyzing innovation. Standardized clinical trial protocols for digital health and streamlined regulatory pathways will reduce time-to-market and development costs.

Conclusion

Sources

1. Research and Markets - FemTech Market Report
2. Fortune Business Insights - FemTech Market
3. FemTech Health - Market Overview
4. Grand View Research - FemTech Market Report
5. Global Market Insights - FemTech Market
6. Galen Growth - FemTech's Rise and Roadblocks
7. FemTech World - Investment in Women's Health 2024
8. Globe Newswire - FemTech Focused Insights Report 2024